23.06.2026 Cancer Research in the Fourth Dimension

ERC Advanced Grant for Molecular Oncologist Thorsten Stiewe Opens New Perspectives for Precision Oncology

Molecular oncologist Prof. Dr. Thorsten Stiewe of Marburg University has been awarded an ERC Advanced Grant from the European Research Council (ERC). The project “TP53 Variant Complexity in Context: Multidimensional Functional Profiling for Precision Oncology” (TP53in4D) will receive approximately 2,500,000 euros in funding over the next five years. The goal of the research is to systematically characterize, for the first time, the biological effects of cancer-associated mutations across multiple dimensions simultaneously. The focus is on the tumor suppressor gene TP53, which is mutated more frequently than any other known cancer gene. Using newly developed experimental methods, the team aims to understand how different mutations behave in different genetic, cellular, and biological contexts—thereby closing a key knowledge gap between the decoding of the genome and its medical interpretation.

Systematically linking mutations to biological function or dysfunction

For Stiewe, the funding represents both recognition and an opportunity for further development. His research was already funded by an ERC Grant from 2010 to 2016; now, the Advanced Grant enables the next major step forward. The project follows a vision that extends far beyond a single cancer gene: “We want to create a scalable framework to systematically decipher the functional significance of mutations in the future,” says Stiewe.

With TP53in4D, the researchers aim to map cancer mutations in four biological dimensions for the first time: from the individual mutation, through the respective cell type and genetic background, to the tumor microenvironment. This will yield a multidimensional functional profile designed to reveal why the same genetic alteration can have completely different consequences in different tumors. This research thus offers a new perspective on the complexity of cancer—and on the mechanisms by which genetic changes exert their effects.

In doing so, the TP53in4D model project addresses one of the central challenges of precision medicine: While genetic data can now be generated at high speed, the gap between the detection of mutations and the understanding of their biological significance is growing. The Marburg-based research aims to help close precisely this knowledge gap.

“The ERC Advanced Grant is one of the most prestigious and highly competitive research grants worldwide. The fact that Thorsten Stiewe was able to secure funding again following a previous ERC grant underscores the international visibility and scientific excellence of his work,” says Prof. Dr. Gert Bange, Vice President for Research at Marburg University. “The project combines innovative genomic technologies with state-of-the-art single-cell and systems approaches. It opens up the possibility of understanding the functional consequences of genetic variation not in isolation, but within a complex biological context. Such work lays the foundation for the next generation of data-driven biomedical research.”

Personalized Cancer Medicine

In the long term, the results could help interpret genetic findings in cancer patients with significantly greater precision and better support individualized treatment decisions. Furthermore, the researchers led by Thorsten Stiewe expect that TP53in4D will generate new methodological tools and datasets that will also be useful for many other disease-relevant genes. The research thus looks far beyond today’s diagnostic methods: It lays the groundwork for a form of medicine that can not only read genetic information but also understand its biological complexity—and opens new paths toward truly personalized cancer medicine.